Shari Orlanski

Shari Orlanski

Auto-generated profile, based on publicly available information

Shari Orlanski

Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2022 in Genome Biology
Verified
Journal Article
Open access
PDF file
EKEfrat Katsman
Efrat Katsman
SOShari Orlanski
Shari Orlanski
FMFilippo Martignano
Filippo Martignano
IFIlana Fox-Fisher
Ilana Fox-Fisher
RSRuth Shemer
Ruth Shemer
BBBenjamin P. Berman
Benjamin P. Berman
The Oxford Nanopore (ONT) platform provides portable and rapid genome sequencing, and its ability to natively profile DNA methylation without complex sample processing is attractive for point-of-care real-time sequencing. We recently demonstrated ONT shallow whole-genome sequencing to detect copy number alterations (CNAs) from the circulating tumor DNA (ctDNA) of cancer patients. Here, we show that cell type and cancer-specific methylation changes can also be detected, as well as cancer-associated fragmentation signatures. This feasibility study suggests that ONT shallow WGS could be a powerful tool for liquid biopsy. Graphical Abstract

19 October 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
EKEfrat Katsman
Efrat Katsman
SOShari Orlanski
Shari Orlanski
FMFilippo Martignano
Filippo Martignano
IFIlana Fox-Fisher
Ilana Fox-Fisher
RSRuth Shemer
Ruth Shemer
BBBenjamin P. Berman
Benjamin P. Berman
The Oxford Nanopore (ONT) platform provides portable and rapid genome sequencing, and its ability to natively profile DNA methylation without complex sample processing is attractive for clinical sequencing. We recently demonstrated ONT shallow whole-genome sequencing to detect copy number alterations (CNA) from the circulating tumor DNA (ctDNA) of cancer patients. Here, we show that cell-type and cancer-specific methylation changes can also be detected, as well as cancer-associated fragmentation signatures. This feasibility study suggests that ONT shallow WGS could be a powerful tool for liquid biopsy, especially real-time medical applications.